Related Experiment Video
Updated: Sep 20, 2025
06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
387
Association between Breast Cancer Polygenic Risk Score and Chemotherapy-Induced Febrile Neutropenia: Null Results.
Seeu Si Ong1,2, Peh Joo Ho1,2,3, Alexis Jiaying Khng1
1Women's Health and Genetics, Genome Institute of Singapore, 60 Biopolis Street, Genome, #02-01, Singapore 138672, Singapore.
Cancers
|June 10, 2022
Summary
Breast cancer polygenic risk scores (PRS) did not show a significant association with chemotherapy-induced neutropenia or febrile neutropenia (FNc) in Asian patients. Further research is needed to understand genetic links to chemotherapy toxicity.
Area of Science:
- Oncology
- Genetics
- Pharmacogenomics
Background:
- Investigating genetic predispositions for chemotherapy-induced toxicity is crucial in breast cancer (BC) treatment.
- Previous studies explored links between BC susceptibility variants and treatment toxicities.
- This study focuses on Asian BC patients to assess the association between a BC polygenic risk score (PRS) and chemotherapy-induced neutropenia and febrile neutropenia (FNc).
Purpose of the Study:
- To evaluate the association between a 313-marker-based BC polygenic risk score (PRS) and chemotherapy-induced neutropenia and febrile neutropenia (FNc) in Asian BC patients.
- To determine if PRS, weighted for overall, ER-positive, and ER-negative BC risk, predicts neutropenia or FNc.
- To compare PRS distributions in patients with and without neutropenia-related outcomes.
Main Methods:
- An observational case-control study included Asian BC patients undergoing chemotherapy.
- Patients were categorized into groups: FNc (161), neutropenia (219), and no neutropenia (936).
- A continuous PRS was calculated using weighted risk alleles; PRS distributions were compared using two-sample t-tests, and odds ratios (OR) were estimated for PRS associations with neutropenia/FNc.
Main Results:
- No significant differences in PRS distributions were observed between cases and controls.
- Higher PRS overall quartiles showed a negative correlation with neutropenia or FNc, but this was not statistically significant.
- No statistically significant association was found for PRS per standard deviation increase with neutropenia (OR: 0.91) or FNc (OR: 0.87); no dose-dependent trend was noted for ER-positive or ER-negative PRS.
Conclusions:
- The study found no strong association between breast cancer polygenic risk score (PRS) and the development of chemotherapy-induced neutropenia or febrile neutropenia (FNc) in the studied Asian population.
- These findings suggest that the investigated BC PRS may not be a reliable predictor of these specific chemotherapy toxicities.
- Further investigation into genetic factors influencing chemotherapy-induced toxicity is warranted.
More Related Videos
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
267
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
267
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
01:21Cancer Survival Analysis
458
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
458
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
332
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
332